TuHURA Biosciences (NASDAQ:HURA - Free Report) - Investment analysts at Zacks Small Cap issued their Q2 2025 EPS estimates for TuHURA Biosciences in a research note issued to investors on Tuesday, February 4th. Zacks Small Cap analyst J. Vandermosten expects that the company will post earnings per share of ($0.09) for the quarter. Zacks Small Cap also issued estimates for TuHURA Biosciences' Q3 2025 earnings at ($0.15) EPS, Q4 2025 earnings at ($0.15) EPS, Q1 2026 earnings at ($0.17) EPS and Q2 2026 earnings at ($0.17) EPS.
Other research analysts have also issued reports about the company. RODMAN&RENSHAW upgraded TuHURA Biosciences to a "strong-buy" rating in a report on Thursday, December 19th. Rodman & Renshaw assumed coverage on TuHURA Biosciences in a research note on Thursday, December 19th. They issued a "buy" rating and a $11.00 price objective for the company. Finally, Maxim Group assumed coverage on shares of TuHURA Biosciences in a research note on Tuesday, November 5th. They set a "buy" rating and a $15.00 target price on the stock.
Read Our Latest Research Report on TuHURA Biosciences
TuHURA Biosciences Stock Down 4.3 %
HURA stock traded down $0.19 during midday trading on Wednesday, hitting $4.27. The company's stock had a trading volume of 173,175 shares, compared to its average volume of 218,133. The firm has a 50-day moving average of $4.78. TuHURA Biosciences has a 52-week low of $2.84 and a 52-week high of $14.60.
Institutional Inflows and Outflows
Several institutional investors and hedge funds have recently made changes to their positions in HURA. Charles Schwab Investment Management Inc. acquired a new stake in TuHURA Biosciences during the 4th quarter worth $61,000. Apollon Wealth Management LLC acquired a new stake in shares of TuHURA Biosciences in the 4th quarter valued at about $253,000. Finally, Suncoast Equity Management acquired a new stake in shares of TuHURA Biosciences in the 4th quarter valued at about $421,000. 0.62% of the stock is owned by institutional investors and hedge funds.
About TuHURA Biosciences
(
Get Free Report)
TuHURA Biosciences, Inc NASDAQ: HURA is a Phase 3 registration-stage immuno-oncology company developing novel technologies to overcome resistance to cancer immunotherapy. TuHURA's lead innate immune response agonist candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors.
See Also
Before you consider TuHURA Biosciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and TuHURA Biosciences wasn't on the list.
While TuHURA Biosciences currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
